Morgan Stanley Issues Pessimistic Forecast for Eikon Therapeutics (NASDAQ:EIKN) Stock Price

Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) had its price target lowered by analysts at Morgan Stanley to $30.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock.

EIKN has been the topic of a number of other reports. Wall Street Zen raised shares of Eikon Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 14th. Mizuho upgraded shares of Eikon Therapeutics to a “strong-buy” rating in a report on Wednesday, September 16th. Wedbush reduced their price objective on shares of Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating for the company in a research note on Friday, August 14th. Weiss Ratings raised shares of Eikon Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, November 13th. Finally, HC Wainwright assumed coverage on shares of Eikon Therapeutics in a report on Friday, October 16th. They set a “buy” rating and a $23.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $24.33.

Check Out Our Latest Stock Analysis on Eikon Therapeutics

Eikon Therapeutics Stock Down 7.9%

Shares of EIKN stock opened at $4.76 on Wednesday. The business’s fifty day moving average price is $7.11 and its 200 day moving average price is $9.94. Eikon Therapeutics has a 1-year low of $4.72 and a 1-year high of $17.40.

Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($1.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.74) by $0.15. As a group, equities research analysts anticipate that Eikon Therapeutics will post -7.00 EPS for the current year.

Insider Transactions at Eikon Therapeutics

In other news, major shareholder Group Iv Gp Lp Column acquired 89,200 shares of Eikon Therapeutics stock in a transaction that occurred on Thursday, September 3rd. The stock was purchased at an average cost of $11.56 per share, with a total value of $1,031,152.00. Following the completion of the acquisition, the insider owned 89,200 shares in the company, valued at $1,031,152. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Institutional Trading of Eikon Therapeutics

Large investors have recently bought and sold shares of the company. BlackRock Inc. increased its position in shares of Eikon Therapeutics by 29.0% in the second quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock valued at $55,873,000 after buying an additional 962,046 shares in the last quarter. Regents of The University of California acquired a new position in shares of Eikon Therapeutics during the 3rd quarter worth $5,106,000. State Street Corp raised its stake in shares of Eikon Therapeutics by 71.9% during the 3rd quarter. State Street Corp now owns 608,838 shares of the company’s stock worth $4,895,000 after buying an additional 254,745 shares during the last quarter. StepStone Group LP boosted its position in shares of Eikon Therapeutics by 32.4% in the 3rd quarter. StepStone Group LP now owns 523,467 shares of the company’s stock worth $4,209,000 after buying an additional 128,127 shares in the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new stake in shares of Eikon Therapeutics in the 2nd quarter worth about $3,341,000.

Eikon Therapeutics Company Profile

(Get Free Report)

Eikon Therapeutics is a biopharmaceutical company focused on discovering and developing medicines for serious diseases, including cancer. The company uses advanced imaging, computational biology and drug-discovery methods to study how proteins behave in living cells and identify potential therapeutic targets. Founded in 2019 by Roger Perlmutter, a former head of Merck Research Laboratories, Eikon is based in California. Its work is centered on research and development; the company is not known for marketed medicines.

Further Reading

Analyst Recommendations for Eikon Therapeutics (NASDAQ:EIKN)

Receive News & Ratings for Eikon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eikon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.